PharmaBlock Convenes Global Industry Leaders in Zurich to Advance Green Chemistry for Sustainable Pharmaceutical Manufacturing
ZURICH, July 20, 2026 /PRNewswire/ — As Europe experienced one of its hottest Junes on record, with prolonged…
Myricx Bio to be Acquired by Novartis to Advance Next-Generation ADC Payloads for Oncology with Novel NMTi Platform
Potential first-in-class N-myristoyltransferase inhibitor (NMTi) ADC payload with a differentiated mechanism of actionCombines oncology expertise of Novartis with…
Brandon Capital Announces Agreement for Novartis to Acquire Portfolio Company Myricx Bio to Advance New Class of Cancer Therapeutics
MELBOURNE, Australia, July 06, 2026 (GLOBE NEWSWIRE) — Brandon Capital, Australasia’s leading life sciences venture capital firm, today…
Alps Group Inc Launches Patient-Derived Organoid Program to Advance Personalized Cancer Care in Southeast Asia
Agreement Marks Company’s Expansion into Precision Oncology Testing, with the Goal of Establishing Malaysia’s First Clinically Validated PDO…
Zurich Insurance (Hong Kong) and YAS announce embedded insurance for robots
Driving AI and robotics adoption in Hong Kong with innovative InsurTech HONG KONG, June 16, 2026 /PRNewswire/ —…
New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength
Late-breaking Phase III IgAN data for Vanrafia ALIGN and Fabhalta APPLAUSE-IgAN studies to be presented124-week Phase I/II zigakibart…
NeuroCatch Inc. Announces Strategic Partnership with The Geneva Foundation to Advance Cognitive Health Research for Military Personnel
Vancouver, British Columbia–(Newsfile Corp. – May 12, 2026) – NeuroCatch Inc., a leader in objective cognitive brain…
Falcon Copper and Glencore Sign MoU to Advance U.S. Critical Minerals Supply Chain
Fort Collins, Colorado–(Newsfile Corp. – April 30, 2026) – Falcon Copper Corp. (“Falcon Copper” or the “Company”)…
Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management
Company announcement – No. 11 / 2026 Zealand Pharma and Roche to advance petrelintide, an amylin analog, to…
Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors
– Acquisition brings together Excellergy’s differentiated trifunctional allergic effector cell response inhibitors (ECRIs) and the development expertise of…